



Name of the medicinal product

VISIPAQUE 270 mg I/ml and 320 mg I/ml

Oualitative and auantitative composition

Active ingredient	Strength	Content pr. ml.	
Iodixanol (INN)	270 mg I/ml	550 mg equiv. 270 mg l	
Iodixanol (INN)	320 mg I/ml	652 mg equiv. 320 mg l	

Iodixanol is a non-ionic, dimeric, hexaiodinated, watersoluble X-ray contrast medium.

Pure aqueous solutions of iodixanol in all clinical relevant concentrations have a lower osmolality than whole blood and the corresponding strengths of the non-ionic monomeric contrast media. VISIPAOUE is made isotonic with normal body fluids by addition of electrolytes. The osmolality and viscosity values of VISIPAQUE are as follows:

Concentration	Osmolality* mOsm/kg H ₂ O	Viscosity	Viscosity (mPa·s)	
	37°C	20°C	37°C	
270 mg I/ml	290	11.3	5.8	
320 mg I/ml	290	25.4	11.4	

* Method: Vapour - pressure osmometry.

270 mg I/ml: This medicinal product contains 0.76 mg (0.03 mmol) sodium per ml. To be taken into consideration by patient on a controlled sodium diet.

320 mg I/ml: This medicinal product contains 0.45 mg (0.02 mmol) sodium per ml. To be taken into consideration by patient on a controlled sodium diet (see Special warnings and precautions for use).

Pharmaceutical form

Solution for injection

VISIPAQUE injections are supplied ready to use as clear, colourless to pale yellow aqueous solutions.

Clinical particulars

Therapeutic indications

This medicinal product is for diagnostic use only.

X-ray contrast medium for use in adults for cerebral angiography (conventional), peripheral angiography, (conventional), abdominal angiography (i.a. DSA), urography, venography, CT-enhancement and studies of the gastrointestinal tract, Lumbar, thoracic and cervical myelography. Arthrography and hysterosalpingography (HSG). And for use in children for cardioangiography, urography, CT-enhancement and studies of the gastrointestinal tract.

Posology and method of administration

The dosage may vary depending on the type of examination, the age, weight, cardiac output and general condition of the patient and the technique used. Usually approximately the same iodine concentration and volume is used as with other iodinated X-ray contrast media in current use, but adequate diagnostic information has also been obtained in some studies with iodixanol injection with somewhat lower iodine concentration. Adequate hydration should be assured before and after administration as for other contrast media. The product is for intravenous, intra-arterial and intrathecal use, and for use in body cavities.

The following dosages may serve as a guide. The doses given for intra-arterial use are for single injections that may be repeated.

Indication/Investigation	Concentration	Volume	
Intra-arterial use Arteriographies			
selective cerebral	270/320 ⁽¹⁾ mg I/ml	5-10 ml per inj.	
aortography	270/320 mg I/ml		
peripheral	270/320 mg l/ml		
selective visceral i.a.DSA	270 mg l/ml	10-40 ml per inj.	
Cardioangiography Adults			
Left ventricle and aortic root inj.	, 320 mg I/ml	30-60 ml per inj.	
Selective coronary arteriography	320 mg I/ml	4-8 ml per inj.	
Children	270/320 mg l/ml	Depending on age, weight and pathology (recommended max total dose 10 ml/kg).	
		total 0030 10 mi/ kg/.	
Intravenous use			
Urography	270/220	40.00 ml ^[2]	
Adults Children < 7 kg	270/320 mg l/ml 270/320 mg l/ml		
Children > 7 kg	270/320 mg l/ml		
Venography	270 mg I/ml		
CT-enhancement	170/200 14	F0 1F0	
CT of the head, <i>adults</i> CT of the body, <i>adults</i>	270/320 mg l/ml 270/320 mg l/ml		
<i>Children</i> , CT of the head and body	270/320 mg I/ml	2-3 ml/kg up to 50 ml (in a few cases up to 150 ml may be given)	
Intrathecal use	270 mg l/ml	10.12 m ^{[[3]}	
Lumbar and thoracic myelography	270 mg l/ml or		
(lumbar injection)	320 mg l/ml	10 ml ⁽³⁾	
Cervical myelography (cervical or lumbar injection)	270 mg l/ml or	10-12 ml (3)	
	320 mg l/ml	10 ml (3)	
Use in body cavities			
Arthrography	270 mg l/ml	The dosage must be adjusted individually to allow optimal visualisation 1 - 15 ml 5 - 10 ml	
Hysterosalpingography (HSG)	270 mg l/ml	The recommended dose may be exceeded several times due to e.g. backflow into the vagina (up to <u>40 ml</u> ha been studied).	
Gastrointestinal studies Oral use			
A <i>dults</i> Follow through	320 mg I/ml		
Oesophagus	320 mg I/ml		
Stomach	320 mg I/ml		
Children	270/320 mg I/ml	studied	
		10-240 ml has been studied	
Rectal use			
Children	270/320 mg I/ml	30 – 400 ml has been studied	

(1) Both strengths are documented, but 270 mg I/ml is recommended in most cases. (2) 80 ml may be exceeded in selected cases. (3) To minimize possible adverse reactions a total dose of 3.2 g iodine should not be

exceeded

Elderly: As for other adults.

Contraindications

Hypersensitivity to the active substance or to any of the excipients. Manifest thyrotoxicosis.

Special warnings and precautions for use

Special precautions for use of non-ionic contrast media in general

A positive history of allergy, asthma, or untoward reactions to iodinated contrast media indicates a need for special caution. Premedication with corticosteroids or histamine H, and H₂ antagonists might be considered in these cases.

The risk of serious reactions in connection with use of VISIPAQUE is regarded as minor. However, iodinated contrast media may provoke anaphylactoid reactions or other manifestations of hypersensitivity. A course of action should therefore be planned in advance, with necessary drugs and equipment available for immediate treatment, should a serious reaction occur. It is advisable always to use an indwelling cannula or catheter for quick intravenous access throughout the entire X-ray procedure.

The possibility of hypersensitivity including serious, lifethreatening, fatal anaphylactic/ anaphylactoid reactions should always be considered. The majority of serious undesirable effects occur within the first 30 minutes. Late onset (that is 1 hour or more after application) hypersensitivity reactions can occur.

Patients should be observed for at least 30 minutes after administration of VISIPAOUE.

Patients using beta blockers may present with atypical symptoms of hypersensitivity which may be misinterpreted as a vagal reaction.

Coagulopathy:

Non-ionic, iodinated contrast media inhibit blood coagulation in vitro less than ionic contrast media. Clotting has been reported when blood remains in contact with syringes containing contrast media including non-ionic media. The use of plastic syringes in place of glass syringes has been reported to decrease but not eliminate the likelihood of in vitro clotting.

Serious, rarely fatal, thromboembolic events causing myocardial infarction and stroke have been reported during angio-cardiographic procedures with both ionic and non-ionic contrast media. Numerous factors, including length of procedure, catheter and syringe material, underlying disease state, and concomitant medications, may contribute to the development of thromboembolic events. For these reasons, meticulous angiographic techniques are recommended, including close attention to guide wire and catheter manipulation, use of manifold systems and/or three-way stopcocks, frequent catheter flushing with heparinized saline solutions, and minimizing the length of the procedure. Advanced life support facilities should be readily available.

Hvdration

Adequate hydration should be assured before and after contrast media administration. This applies especially to patients with multiple myeloma, diabetes mellitus, renal dysfunction, as well as to infants, small children and elderly patients. Young infants (age < 1 year) and especially neonates are susceptible to electrolyte disturbance and haemodynamic alternations.

Cardio-circulatory reactions

Care should also be taken in patients with serious cardiac disease and pulmonary hypertension as they may develop haemodynamic changes or arrhythmias. Rarely severe lifethreatening reactions and fatalities of cardiovascular origin such as cardiac-, cardio-respiratory arrest and myocardial infarction have occurred.

CNS disturbances

Patients with acute cerebral pathology, tumours or a history of epilepsy are predisposed for seizures and merit particular care. Also alcoholics and drug addicts have an increased risk for seizures and neurological reactions. In regard to intravascular application care should be taken in patients with acute stroke or acute intracranial bleeding, in patients with altered blood brain barrier, cerebral oedema or acute demyelinisation.

Renal reactions

Major risk factor for contrast medium-induced nephropathy is underlying renal dysfunction.

Diabetes mellitus and the volume of iodinated contrast medium administered are contributing factors in the presence of renal dysfunction. Additional concerns are dehydration, advanced arteriosclerosis, poor renal perfusion and the presence of other factors that may be nephrotoxic, such as certain medications or major surgery.

Preventive measures include

- Identification of high risk patients
- Ensuring adequate hydration. If necessary by maintaining an i.v. infusion from before the procedure until the contrast medium has been cleared by the kidneys.
- Avoiding additional strain on the kidneys in the form of nephrotoxic drugs, oral cholecystographic agents, arterial clamping, renal arterial angioplasty, or major surgery, until the contrast medium has been cleared.
- Dose reducing to a minimum. - Postponing a repeat contrast medium examination until renal function returns to pre-examination levels.

lodinated contrast agents can be used by patients on haemodialysis as the agents are removed by the dialysis process.

Diabetic patients receiving metformin To prevent lactic acidosis, serum creatinine level should be measured in diabetic patients treated with metformin prior to intravascular administration of iodinated contrast medium. Normal serum creatinine / renal function: Administration of metformin should be stopped at the time of administration of contrast medium and not resumed for 48 hours or until renal function / serum creatinine is normal. Abnormal serum creatinine / renal function: Metformin should be stopped and the contrast medium examination delayed for 48 hours. Metformin should only be restarted if renal function / serum creatinine is unchanged. In emergency cases where renal function is abnormal or unknown, the physician should evaluate the risk / benefit of the contrast medium examination, and precautions should be implemented: Metformin should be stopped, patient hydrated, renal function monitored and patient observed for symptoms of lactic acidosis.

Impaired renal and hepatic function

Particular care is required in patients with severe disturbance of both renal and hepatic function as they may have significantly delayed contrast medium clearance. Patients on haemodialysis may receive contrast media for radiological procedures. Correlation of the time of contrast media injection with the haemodialysis session is unnecessary because there is no evidence that haemodialysis protects patients with impaired renal function from contrast medium induced nephropathy.

Myasthenia gravis

The administration of iodinated contrast media may aggravate the symptoms of myasthenia gravis. Phaeochromocytoma

In patients with phaeochromocytoma undergoing interventional procedures, alpha blockers should be given as prophylaxis to avoid a hypertensive crisis.

Disturbances in thyroid function

Patients at risk of thyrotoxicosis should be carefully evaluated before any use of iodinated contrast medium. Special care should be exercised in patients with hyperthyroidism. Patients with multinodular goitre may be at risk of developing hyperthyroidism following injection of iodinated contrast media.

Paediatric population

One should also be aware of the possibility of inducina transient hypothyroidism in premature infants receiving

contrast media. Thyroid function should be checked in neonates during the first week of life, following administration of iodinated contrast agents to the mother during pregnancy. Repeat testing of thyroid function is recommended at 2 to 6 weeks of age, particularly in low birth weight newborn or premature newborn.

See also Pregnancy and lactation.

Extravasation

Extravasation of VISIPAQUE has not been reported, but it is likely that VISIPAQUE due to its isotonicity gives rise to less local pain and extravascular oedema than hyperosmolar contrast media. In case of extravasation, elevating and cooling the affected site is recommended as routine measures. Surgical decompression may be necessary in cases of compartment syndrome.

Observation-time:

After contrast medium administration the patient should be observed for at least 30 minutes, since the majority of serious side effects occurs within this time. However, experience shows that hypersensitivity reactions may appear up to several hours or days post injection.

Intrathecal use:

Following myelography the patient should rest with the head and thorax elevated by 20° for one hour. Thereafter he/she may ambulate carefully but bending down must be avoided. The head and thorax should be kept elevated for the first 6 hours if remaining in bed. Patients suspected of having a low seizure threshold should be observed during this period. Outpatients should not be completely alone for the first 24 hours.

Hysterosalpingography

Hysterosalpingography should not be performed during pregnancy or in the presence of acute pelvic inflammatory disease (PID)

Interaction with other medicaments and other forms of interactions

All iodinated contrast media may interfere with tests on thyroid function, thus the iodine binding capacity of the thyroid may be reduced for up to several weeks.

High concentrations of contrast media in serum and urine can interfere with laboratory tests for bilirubin, proteins or inorganic substances (e.g. iron, copper, calcium and phosphate). These substances should therefore not be assayed on the day of examination.

Use of iodinated contrast media may result in a transient impairment of renal function and this may precipitate lactic acidosis in diabetics who are taking metformin (see Special warnings and special precautions for use).

Patients treated with interleukin-2 less than two weeks previous to an iodinated contrast medium injection have been associated with an increased risk for delayed reactions (flu-like symptoms or skin reactions).

All iodinated contrast media may interfere with tests on thyroid function, thus the iodine binding capacity of the thyroid may be reduced for up to several weeks.

High concentrations of contrast media in serum and urine can interfere with laboratory tests for bilirubin, proteins or inorganic substances (e.g. iron, copper, calcium and phosphate). These substances should therefore not be assayed on the day of examination.

Pregnancy and lactation

Preanancv

The safety of VISIPAQUE for use in human pregnancy has not been established. An evaluation of experimental animal studies does not indicate direct or indirect harmful effects with respect to reproduction, development of the embryo or fetus, the course of gestation and peri- and postnatal development.

Since, wherever possible, radiation exposure should be avoided during pregnancy, the benefits of any X-ray examination, with or without contrast media, should be carefully weighed against the possible risk. The product should not be used in pregnancy unless benefit outweighs risk and it is considered essential by the physician.

Breast-feedina

Contrast media are poorly excreted in human breast milk and minimal amounts are absorbed by the intestine. Breast feeding may be continued normally when iodinated contrast media are given to the mother.

Effects on ability to drive and use machines

No studies on the ability to drive or use machines have been performed however, it is not advisable to drive a car or use machines during the first 24 hours following intrathecal examination.

Undesirable effects

Below are listed possible side effects in relation with radiographic procedures which include the use of VISIPAOUE.

Undesirable effects associated with VISIPAQUE are usually mild to moderate and transient in nature. Serious reactions as well as fatalities are only seen on very rare occasions, these may include acute-on-chronic renal failure, acute renal failure, anaphylactic or anaphylactoid shock, hypersensitivity reaction followed by cardiac reactions (Kounis' syndrome), cardiac or cardio-respiratory arrest and myocardial infarction. Cardiac reaction may be promoted by the underlying disease or the procedure.

Hypersensitivity reactions may present as respiratory or cutaneous symptoms like dyspnoea, rash, erythema, urticaria, pruritus, severe skin reactions, angioneurotic oedema, hypotension, fever, laryngeal oedema, bronchospasm or pulmonary oedema. In patients with autoimmune diseases cases of vasculitis and SJS-like syndrome were observed.

They may appear either immediately after the injection or up to a few days later.

Hypersensitivity reactions may occur irrespectively of the dose and mode of administration and mild symptoms may represent the first signs of a serious anaphylactoid reaction/ shock.

Administration of the contrast medium must be discontinued immediately and, if necessary, specific therapy instituted via the vascular access. Patients using betg blockers may present with atypical symptoms of hypersensitivity which may be misinterpreted as a vagal reaction.

A minor transient increase in serum creatinine is common after iodinated contrast media, but is usually of no clinical relevance

The frequencies of undesirable effects are defined as follows: Very common ($\geq 1/10$), common ($\geq 1/100$ to < 1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000) and not known (cannot be estimated from the available data)

The listed frequencies are based on internal clinical documentation and published studies, comprising more than 48,000 patients.

Intravascular administration:

Blood and lymphatic system disorders Not known: Thrombocytopenia

Immune system disorders:

Uncommon: Hypersensitivity

Not known: Anaphylactoid reaction, anaphylactoid shock; In patients with autoimmune diseases cases of vasculitis and Steven- Johnson like syndrome were observed.

Psychiatric disorders: Very rare: Agitation, anxiety Not known: Confusional state

Nervous system disorders:

Uncommon: Headache

Rare: Dizziness

Very rare: Cerebrovascular accident, sensory abnormalities including taste disturbance, paraesthesia, amnesia, syncope.

Not known: Coma, motor dysfunction, disturbance in consciousness, convulsion, transient contrast-induced encephalopathy (including amnesia, hallucination, tremor).

Eve disorders:

Very rare: Transient cortical blindness, visual impairment. Cardiac disorders:

Rare: Arrhythmia (including bradycardia, tachycardia). Not known: Cardiac failure, cardiac or cardio- respiratory arrest, myocardial infarction, conduction abnormalities, ventricular hypokinesia, coronary artery thrombosis, angina pectoris, spasms of coronary arteries

Vascular disorders: Uncommon: Flushing Rare: Hypotension Very rare: Hypertension, ischaemia Not known: Arterial spasm, thrombosis, thrombophlebitis, shock.

Respiratory, thoracic and mediastinal disorders: Rare: Cough

Very rare: Dyspnoea Not known: Pulmonary oedema, respiratory arrest, respiratory failure

Gastrointestinal disorders:

Uncommon: Nausea, vomitina

Very rare: Abdominal pain/discomfort Not known: Acute pancreatitis, pancreatitis aggravated, salivary gland enlargement

Skin and subcutaneous system disorders

Uncommon:Rash, pruritus, urticaria Very rare: angioedema, erythema

Not known: Bullous dermatitis. Stevens-Johnson syndrome. erythema multiforme, toxic epidermal necrolysis, acute generalised exanthematous pustulosis, drug rash with eosinophilia and systemic symptoms, drug eruption, dermatitis allergic, skin exfoliation

Musculoskeletal and connective tissue disorders: Very rare: Back pain, muscle spasm Not known: Arthralgia

Renal and urinary disorders:

Very rare: Impairment of renal function including acute renal failure

General disorders and administration site conditions: Uncommon: Feeling hot, chest pain

Rare: Pain, discomfort, shivering (chills), pyrexia, administration site reactions including extravasation Very rare: Feeling cold, asthenic conditions (e.g. malaise, fatiaue)

Injury, poisoning and procedural complications: Not known: lodism

Intrathecal administration:

Undesirable effects following intrathecal use may be delayed and present some hours or even days after the procedure. The frequency is similar to lumbar puncture alone. Meningeal irritation giving photophobia and meningism and frank chemical meningitis have been observed with other non-ionic contrast media. The possibility of infective meningitis should also be considered.

Immune system disorders:

Not known: Hypersensitivity, including anaphylactic/ anaphylactoid reactions

Nervous system disorders:

Uncommon: Headache (may be severe and lasting) Not known: Dizziness, transient contrast induced encephalopathy (including amnesia, hallucinations. confusion.

Gastrointestinal disorders:

Uncommon: Vomiting

Not known: Nausea

Musculoskeletal and connective tissue disorders: Not known: Muscle spasm

General disorders and administration site conditions: Not known: Shivering, pain at injection site

Hysterosalpingography (HSG):

Immune system disorders: Not known: Hypersensitivity

Nervous system disorders: Common: Headache

Gastrointestinal disorders: Very common: Abdominal pain Common: Nausea Not known: Vomitina

Reproductive system and breast disorders: Very common: Vaginal haemorrhage

General disorders and administration site conditions: Common: Pyrexia

Not known: Shivering, injection site reaction

Arthrography:

Immune system disorders: Not known: Hypersensitivity, including anaphylactic/ anaphylactoid reactions.

General disorders and administration site conditions: Common: Injection site pain Not known: Shivering

Examination of the GI tract:

Immune system disorders:

Not known: Hypersensitivity, including anaphylactic/ anaphylactoid reactions.

Gastrointestinal disorders: Common: Diarrhoea, abdominal pain, nausea Uncommon: Vomiting

General disorders and administration site reaction Not known: Shivering

Overdose

Overdosage is unlikely in patients with a normal renal function. The duration of the procedure is important for the renal tolerability of high doses of contrast media (t $_{10}$ ~ 2 hours). In the event of accidental overdosing, the water and electrolyte losses must be compensated by infusion. Renal function should be monitored for at least the next 3 days. If needed, haemodialysis may be used to remove iodixanol from the patient's system. There is no specific antidote. Treatment of overdose is symptomatic.

Pharmacological properties

Pharmacodynamic properties

Pharmacotherapeutic group: X-ray contrast medium, iodinated ATC nr: V08A B09

The organically bound iodine absorbs radiation in the blood vessels/tissues when it is injected. For most of the haemodynamic, clinical-chemical and coagulation parameters examined following intravenous injection of iodixanol in healthy volunteers, no significant deviation from preinjection values has been found. The few changes observed in the laboratory parameters were minor and considered to be of no clinical importance.

VISIPAQUE induces only minor effects on renal function in patients. In diabetic patients with serum creatinine levels of 1.3-3.5 mg/dl, VISIPAQUE use resulted in 3% of patients experiencing a rise in creatinine of ≥ 0.5 mg/dl and 0% of the patients with a rise of \geq 1.0 mg/dl. The release of enzymes (alkaline phosphatase and N-acetyl-B-glucosaminidase) from the proximal tubular cells is less than after injections of non-ionic monomeric contrast media and the same trend is seen compared to ionic dimeric contrast media. VISIPAQUE is also well tolerated by the kidney.

Cardiovascular parameters such as LVEDP, LVSP, heart rate and OT-time as well as femoral blood flow were less influenced after VISIPAOUE than after other contrast media. where measured.

Pharmacokinetic properties

Iodixanol is rapidly distributed in the body with a mean distribution half-life of approximately 21 minutes. The apparent volume of distribution is of the same magnitude as the extracellular fluid (0.26 l/kg b.w.), indicating that iodixanol is distributed in the extracellular volume only.

No metabolites have been detected. The protein binding is less than 2%.

The mean elimination half-life is approximately 2 hours. Iodixanol is excreted mainly through the kidneys by glomerular filtration. Approximately 80% of the administered dose is recovered unmetabolized in the urine within 4 hours and 97% within 24 hours after intravenous injection in healthy volunteers. Only about 1.2% of the injected dose is excreted in faeces within 72 hours. The maximum urinary concentration appears within approximately 1 hour after injection.

No dose dependent kinetics have been observed in the recommended dose range

No specific pharmacokinetic studies have been performed for use in body cavities.

Preclinical safety data

Reproduction studies in rats and rabbits have revealed no evidence of impaired fertility or teratogenicity due to iodixanol.

Pharmaceutical particulars

List of excipients

The following excipients are included: Trometamol. sodium chloride, calcium chloride, sodium calcium edetate, hydrochloric acid (pH adjustment) and water for injections.

The pH of the product is 6.8 - 7.6.

Incompatibilities

No incompatibility has been found. However, VISIPAQUE should not be directly mixed with other drugs. A separate syringe should be used.

Shelf life

See expiry date printed on label.

Special precautions for storage

VISIPAOUE should be stored at up to 30°C protected from light. The product in glass containers and polypropylene bottles may be stored at 37°C for up to 1 month prior to use.

Nature and content of container Glass vials and bottles:

The product is filled in injection vials (20 ml) and infusion bottles (50, 100, 200 and 500 ml). Both containers are made of colourless highly resistant borosilicate glass (Ph.Eur. Type I), closed with chlorobutyl rubber stoppers (Ph.Eur. Type I), and sealed with complete tear off caps with coloured plastic "flip-off" tops.

Polypropylene bottles:

The product is filled in polypropylene bottles.

The bottles of 50, 75, 100, 150, 175, 200 and 500 ml are supplied with a plastic screw cap which is provided with a tamper proof ring.

The product is supplied as:

Glass vials/bottles

270 mgI/ml:	10 vials of 20 ml 10 bottles of 50 ml 10 bottles of 100 ml 6 bottles of 200 ml
320 mgI/ml:	10 vials of 20 ml 10 bottles of 50 ml 10 bottles of 100 ml 6 bottles of 200 ml

Polypropylene bottles

270

270 mgi/ml:	10 bc
-	10 bo
	10 bc
	6 bo
320 mgI/ml:	10 bc
Ū.	10 bo
	10 bo
	10 bo

In certain countries some package sizes may not be available

Instructions for use/handling Like all parenteral products, VISIPAQUE should be inspected visually for particulate matter, discolouration and the integrity of the container prior to use.

The product should be drawn into the syringe immediately before use. Vials are intended for single use only, any unused portions must be discarded.

before administration.

The line running from the auto injector/pump to the patient must be exchanged after each patient. Any unused portions of the contrast medium remaining in the bottle and all connecting tubes must be discarded at the end of the day. When convenient, smaller bottles can also be used. Instructions from the manufacturer of the auto injector/ pump must be followed.

GE Healthcare AS Nycoveien 1-2 P.O. Box 4220 Nydalen NO-0401 OSLO NORWAY Phone +47 23 18 50 50 Fax +47 23 18 60 00

Date of revision of the text

February 2017

Visipaque is a trademark of GE Healthcare. Company

- 10 bottles of 50 ml ottles of 75 ml ottles of 100 ml ottles of 150 ml ottles of 175 ml ottles of 200 ml ottles of 500 ml ottles of 50 ml ottles of 75 ml ottles of 100 ml ottles of 150 ml 10 bottles of 175 ml 10 bottles of 200 ml
- 6 bottles of 500 ml

VISIPAQUE may be warmed to body temperature (37°C)

Additional instruction for auto injector/pump

The 500 ml contrast medium bottles should only be used in connection with auto injectors/pumps approved for this volume. A single piercing procedure should be used.

> Manufactured by: GE Healthcare Ireland Limited IDA Business Park Carrigtohill Co. Cork Ireland

GE and the GE Monogram are trademarks of General Electric